Researchers Develop World’s First AI-Augmented Ova and Parasite Detection Tool
|
By LabMedica International staff writers Posted on 29 Aug 2019 |

Image: ARUP Laboratories and Techcyte have developed the world’s first AI-augmented ova and parasite detection tool (Photo courtesy of Techcyte).
ARUP Laboratories (Salt Lake City, UT, USA), a national reference laboratory engaged in innovative laboratory research and development, and Techcyte (Lindon, UT, USA), a developer of artificial intelligence (AI) based image analysis solutions for the diagnostics industry, have developed the world’s first AI-augmented ova and parasite detection tool.
ARUP, a national clinical and anatomic pathology reference laboratory, is a non-profit enterprise of the University of Utah and offers an extensive test menu of highly complex and unique medical tests. Techcyte, which was founded as a technology transfer from the University of Utah, uses the power of deep machine learning to perform image analysis of whole slide images. Techcyte’s digital diagnostics platform applies the latest in convolutional neural networks to pre-classify the fecal sample images captured by a 3DHISTECH Pannoramic 250-Flash III scanner. Pre-classifying the images using the Techcyte tool allows ARUP’s technologists to efficiently read stained glass slides manually and improves the accuracy of parasite detection.
For laboratorians, digitally enabling the workflow will decrease the physical demands of looking through a microscope for extended periods of time, including eye fatigue and neuromuscular tension. The technology can quickly screen out negative results, allowing laboratorians to spend more time analyzing positive slides. The ova and parasite tool is the first among several projects being co-developed by ARUP and Techcyte. ARUP’s medical expertise and access to samples, combined with Techcyte’s technical ability and digital evaluation platform, will produce high quality algorithms that can be developed and applied to future unmet laboratory needs.
“The collaboration with Techcyte has produced an AI-augmented detection tool that significantly advances our diagnostic capabilities in our parasitology lab,” said Adam Barker, PhD, director of Research and Development at ARUP. “This will allow for faster turnaround times, decreased costs, employee satisfaction and improved patient care.”
“Microscopy-based diagnostic parasitology has remained woefully static for decades. We have successfully developed a pioneering breakthrough with this tool, the likes of which had previously been unimaginable by classically trained microbiologists,” said Dr. Marc Couturier, medical director of ARUP’s Parasitology labs.
“This revolutionary partnership will combine ARUP’s vast expertise and reputation in the market with Techcyte’s AI-based image analysis capabilities to change the way lab diagnostics are performed,” said Ralph Yarro, CEO of Techcyte.
Related Links:
ARUP Laboratories
Techcyte
ARUP, a national clinical and anatomic pathology reference laboratory, is a non-profit enterprise of the University of Utah and offers an extensive test menu of highly complex and unique medical tests. Techcyte, which was founded as a technology transfer from the University of Utah, uses the power of deep machine learning to perform image analysis of whole slide images. Techcyte’s digital diagnostics platform applies the latest in convolutional neural networks to pre-classify the fecal sample images captured by a 3DHISTECH Pannoramic 250-Flash III scanner. Pre-classifying the images using the Techcyte tool allows ARUP’s technologists to efficiently read stained glass slides manually and improves the accuracy of parasite detection.
For laboratorians, digitally enabling the workflow will decrease the physical demands of looking through a microscope for extended periods of time, including eye fatigue and neuromuscular tension. The technology can quickly screen out negative results, allowing laboratorians to spend more time analyzing positive slides. The ova and parasite tool is the first among several projects being co-developed by ARUP and Techcyte. ARUP’s medical expertise and access to samples, combined with Techcyte’s technical ability and digital evaluation platform, will produce high quality algorithms that can be developed and applied to future unmet laboratory needs.
“The collaboration with Techcyte has produced an AI-augmented detection tool that significantly advances our diagnostic capabilities in our parasitology lab,” said Adam Barker, PhD, director of Research and Development at ARUP. “This will allow for faster turnaround times, decreased costs, employee satisfaction and improved patient care.”
“Microscopy-based diagnostic parasitology has remained woefully static for decades. We have successfully developed a pioneering breakthrough with this tool, the likes of which had previously been unimaginable by classically trained microbiologists,” said Dr. Marc Couturier, medical director of ARUP’s Parasitology labs.
“This revolutionary partnership will combine ARUP’s vast expertise and reputation in the market with Techcyte’s AI-based image analysis capabilities to change the way lab diagnostics are performed,” said Ralph Yarro, CEO of Techcyte.
Related Links:
ARUP Laboratories
Techcyte
Latest Industry News
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
- Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more








